Search | Clinical Trials Finder

Conditions: Treatment Resistant Depression
Interventions: Allo-hMSCs, Placebo; Drug
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pre Diabetes, Overweight and Obesity
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 50 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control; Drug
Lead sponsor: Oryn Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Los Angeles, California • Tustin, California • Miami, Florida

Conditions: H1N1 Influenza Healthy Volunteers
Interventions: CR6261, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain, Hip Fractures
Interventions: Femoral Nerve Block; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: New York, New York

Conditions: Musculoskeletal Diseases
Interventions: ACE-083; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Childhood Obesity, Evidence-Based Practice, Food Systems, Food Policy
Interventions: Catalyzing Communities, FICAS Implementation Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 3,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healing
Interventions: Shapes by PolyMem dressing, Shapes by PolyMem Silver Dressing, Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site; Device
Lead sponsor: Ferris Mfg. Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
Interventions: Stem cells; Biological
Lead sponsor: Stemedica Cell Technologies, Inc.; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Gilbert, Arizona • Atlanta, Georgia

Conditions: Healthy
Interventions: Saline, PF-02545920, Ketamine, Placebo; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: New Haven, Connecticut

Conditions: Fibromyalgia
Interventions: ASP8062, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Oceanside, California • Torrance, California + 21 more

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Periocular Fine Wrinkles
Interventions: Split-Face Tixel Treatment With and Without Topical Peptide-Based Cosmeceutical (P-TIOX); Combination Product
Lead sponsor: Main Line Center for Laser Surgery; Other
Eligibility: 30 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ardmore, Pennsylvania

Conditions: Arthritis Knee
Interventions: Clinical Limping Evalution; Other
Lead sponsor: Canary Medical; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Morbid Obesity, Opioid-Related Disorders, Surgery--Complications, Sleep Apnea Syndromes
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
Interventions: Discharge Order Set (DOS), Enhanced Standard Care (ESC); Other
Lead sponsor: Ohio State University; Other
Eligibility: 25 Years to 75 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Tourette Syndrome
Interventions: TEV-50717, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 33
States / cities: Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Healthy
Interventions: PF-06865571, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Heart Failure, Chronic Heart Failure
Interventions: Heartfelt Device installed, Standard care, Heartfelt-guided care, Questionnaires; Device · Other
Lead sponsor: Heartfelt Technologies; Industry
Eligibility: 22 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Little Rock, Arkansas • Hackensack, New Jersey • Bala-Cynwyd, Pennsylvania

Conditions: Subglottic Stenosis (SGS), Pierre Robin Sequence (PRS), Micrognathia, Normal Controls From CT Scans of the Upper Airway
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Eosinophilic Esophagitis
Interventions: AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension; Drug
Lead sponsor: AQILION AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 120 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 15
States / cities: Mobile, Alabama • Sunset, Louisiana • Plymouth, Minnesota + 12 more

Search by objective public record fields.

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

TRE With Physical Activity for Weight Management

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

Improving Pain and Function in Hip Fracture

Phase 1 Study of ACE-083 in Healthy Subjects

Network-Based Support to Help Community Coalition Members Choose and Use Strategies to Improve Child Health

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

Evaluation of Preferences of Consumers and Clinicians for the Management of Shave Biopsy Sites With a PolyMem Formulation Dressing or Current Standard of Care.

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects

A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Effects of P-TIOX and Tixel Combined on Reducing Eye Wrinkles

Quantitative Assessment of Walking (Squawk) With the Canary canturioTM te (CTE) Tibial Extension

Recovery of Ventilation After General Anesthesia in Morbidly Obese Patients

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

The HEARTFELT Study

Functional Modeling of the Pediatric Airway

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)